High throughput screening of our small molecule combinatorial library ident
ified a class of benzoylnaphthalenehydrazones with modest affinity for the
human glucagon receptor. Optimization of this initial hit through a series
of targeted libraries and traditional medicinal chemistry led to ligands wi
th nanomolar affinities. Pharmacological evaluation demonstrated that these
ligands were competitive glucagon receptor antagonists. Intravenous admini
stration of a representative benzoylnaphthalenehydrazone into rats attenuat
ed glucagon-stimulated glucose levels.